Lower rates of pump-related blood clots and stroke were seen in patients who received the centrifugal-flow pump than commercial axial flow pump, according to a study presented by Mandeep R. Mehra, MD, executive director of the Center for Advanced Heart Disease and medical director of the Heart & Vascular Center at Brigham and Women's Hospital in a Late Breaking Clinical Trial at ACC. It provided long-term information about survival, stroke rates and durability about heart-failure patients. The findings of the study are published in the journal New England Journal of Medicine.
"This is a pivotal study in the field of advanced heart failure
," said Mehra. "Left ventricular assist devices have been in development for 40 years and there have been improvements in their technology but several challenges exist, including problems of blood clots forming in these devices, requiring device replacement. The field has been trying to engineer devices that could obviate some or all of these problems, and we report today on some important advances."
‘Stroke rates and re-operation requirement are less frequent when treated with centrifugal-flow pump.’
MOMENTUM 3, sponsored by Abbott Inc., evaluated Abbott's HeartMate 3™ left ventricular assist system, a magnetically-levitated continuous centrifugal-flow circulatory pump, compared to the HeartMate II™. The trial evaluated how many participants, two years after receiving their device, had not suffered a disabling stroke or had an operation to replace or remove a malfunctioning device. A total of 366 patients were randomized to receive either the centrifugal flow pump or the axial flow pump. Scientist report that 151 of 190 patients on the centrifugal flow pump did not experience a disabling stroke or need a re-operation (79.5 percent) compared to 106 of 176 of the patients (60.2 percent) on the axial pump. Only three people who received the centrifugal-flow pump needed a re-operation compared to 30 who received the axial pump. No re-operations occurred due to blood clots in the centrifugal-flow pump. Deaths or disabling strokes were similar between the two groups, but overall, stroke
rates were less frequent in the centrifugal-flow pump group. Bleeding and infection rates were no different between the two groups.
MOMENTUM 3 launched in 2014 and was designed to dramatically reduce the overall timeline for clinical trials. All patients with refractory heart failure who needed a cardiac pump were eligible for the trial, regardless of whether the pump was intended as bridge to transplantation or destination therapy.
"Traditional trials must undergo safety testing, followed by testing in healthier populations, and it can be over a decade before the broader population has access to such therapies," said Mehra. "Removing restrictions based on transplant status resulted in a unique study that has been extremely successful in its enrollment and highly expeditious in delivering results."
The HeartMate 3 includes several technological adaptations intended to reduce risk of complications. The fully magnetically levitated device runs like a bullet train - its rotor has no mechanical bearings in it and pushes the blood using only magnetism. It is designed to reduce shear stress, which is thought to cause blood clots to form in pumps.
In its next phase, MOMENTUM 3 will evaluate 1,028 patients at the two-year mark to further validate the current findings. Results of the full cohort are expected by the end of 2019.